In this article (Clin Cancer Res 2015;21:4811–8), which was published in the November 1, 2015, issue of Clinical Cancer Research (1), the grant support is listed incorrectly. It should read as follows: “This work has been partially funded by the ISCIII through the project PI13/00230 (Health Strategic Action included in the State Plan for Research and Innovation, MINECO), which is cofunded by the European Regional Development Fund (ERDF). Additional funding for this work was provided by Celgene Corporation and by a Stand Up To Cancer Dream Team Translational Research Grant, Grant Number SU2C-AACR-DT0509. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.” The authors regret this error.

1.
Hidalgo
M
,
Plaza
C
,
Musteanu
M
,
Illei
P
,
Brachmann
CB
,
Heise
C
, et al
SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the phase III MPACT trial
.
Clin Cancer Res
2015
;
21
:
4811
8
.